AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03149211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: current standard HAART treatment
Description: Subjects will receive current standard HAART treatment as the active control group.
Study NCT06690723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 plus Dapagliflozin
Description: Vitamin D3 plus Dapagliflozin plus lifestyle modification
Study NCT06690723 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: Lifestyle modification alone
Study NCT06689943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol
Description: Tylenol for children
Study NCT06689943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: Tylenol for children
Study NCT06689761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ColCT
Description: Dietary Supplement: Collagen Participants ingest 15 grams of specific collagen peptides daily
Study NCT06689761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ColET
Description: Dietary Supplement: Collagen Participants ingest 15 grams of specific collagen peptides daily
Study NCT06689761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PlaCT
Description: Dietary Supplement: Placebo. Participants ingest 15 grams of placebo daily
Study NCT06689761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PlaET
Description: Dietary Supplement: Placebo. Participants ingest 15 grams of placebo daily
Study NCT06690944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: The following basic principles and procedures were emphasized when applying the techniques: manual contact, resistance, approximation, verbal commands, and therapist's body mechanics. During stages 1 and 2 of the intervention, the amount of PNF optimal resistance used was necessary to maintain a stable and safe position, with good body alignment, in a manner that produced coordinated movements to generate appropriate motor learning.
Study NCT06690944 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise without proprioceptive neuromuscular facilitation control group
Description: The physical exercise without proprioceptive neuromuscular facilitation control group (CG) intervention consisted of the same activities carried out in the proprioceptive neuromuscular facilitation (PNF) group during Stages 1 and 2, during the same amount of minutes, sessions, and weeks; however, CG intervention did not include specific techniques and basic principles (i.e. approximation and optimal resistance) and procedures of the PNF concept. The activities were instructed and supervised by a trained professional through verbal command. The professional was at stand-by assistant position to prevent accidents.
Study NCT06691919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Endoscopic Necrosectomy with Powered Endoscopic Debridement
Description: Patients will first undergo endoscopic ultrasound-guided cystgastrostomy using an electrocautery-enhanced lumen apposing metallic stent to gain access to the necrosum. Direct Endoscopic Necrosectomy will be performed using the EndoRotor® NecroMax 6.0 PED Catheter which has an outer diameter of 5.1 mm and is compatible with endoscopes that have a working channel of ≥6.0 mm.
Study NCT06691919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transgastric Surgical Necrosectomy
Description: Patients randomized to the surgical arm will undergo open or minimally invasive (laparoscopic) transgastric SN with the aim of creating an ample size cystgastrostomy to perform a complete debridement. In either approach, the peritoneal cavity is entered to identify the stomach through which an anterior gastrotomy is made. The retrogastric necrosum is identified either using a finder needle or ultrasound and accessed through a posterior cystgastrostomy. Transgastric SN is then manually performed, and any cyst fluid fully evacuated. The anterior gastrotomy is then closed allowing any residual necrosis or pancreatic enzyme to efflux into the stomach and enter the upper GI tract. As with endoscopy, patients with retrogastric collections are observed for a sufficient period to ensure full maturation of the necrosum.
Study NCT06696053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transversal therapeutic education
Description: Additional patient consultation for therapeutic education with nurses.
Study NCT06694129 — intervention group
Intervention type: DRUG
Intervention: Entrectinib
Description: Patients in each cohort were treated with Entrectinib.
Study NCT06687902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Digital breast tomosynthesis
Description: In digital breast tomosynthesis (DBT), images are acquired using a specialized X-ray tube that moves in an arc around the breast. This technique captures multiple low-dose images from various angles, typically within a 15° to 60° range. These images are then reconstructed into 1-mm slices to create a 3D representation of the breast, allowing for detailed layer-by-layer evaluation. The number of images acquired varies depending on the size of the breast and the specifications of the equipment but generally ranges from 10 to 25 projections, captured within a few seconds.
Study NCT06689670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle based delivery of INT001 into liver tumors under real-time image guidance
Description: Using ultrasound or CT imaging, the liver tumor is located. Under local anesthesia or, if necessary, intravenous sedation, the needle is inserted through the skin and the needle tip is brought to the center of the liver tumor using image guidance. 1-2 ml of the INT-001 is injected. The needle is removed and a bandaid is applied to the skin entry site. Right after, or as soon as MRI becomes available, MRI is performed to show that the entire tumor has been treated.
Study NCT06688682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP joint injection combined with acupoint injection
Description: PRP acupoint injection
Study NCT06688682 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PRP joint injection combined with acupoint injection
Description: PRP acupoint injection
Study NCT06691152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 Universal CAR-T cells
Description: Three dose groups (1×10\^7/kg, 3×10\^7/kg, 6×10\^7/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
Study NCT06689085 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Description: XYOSTED 50mg, XYOSTED 75 mg, XYOSTED 100 mg
Study NCT06364774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALS20
Description: novel lentiviral vector ALS20
Study NCT06470672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: Anti-TROP-2 ADC
Study NCT06470672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: PD-L1 inhibitor
Study NCT06694519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manometry through the PHENIX series device (model: PHENIX LIBERTY; manufacturer: ELECTRONIC CONCEPT LIGNON INNOVATION, Montpelier, France).
Description: For this manometry the air probe, connected to the Phenix biofeedback system, covered by a latex probe cover lubricated with gel, will be used. In the procedure, the labia majora are opened with one hand and slowly rotated into the vagina while holding the back of the manometric probe with the other hand. Basal tone in g will be measured prior to pelvic floor muscles force measurements. The manometry probe will extract pelvic floor pressure signals by measuring both your basal tone and the maximum pressure held for 10 seconds in three measurements, the average of the three being calculated at the command, 'contract as hard as you can for as long as possible'.
Study NCT06694519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PFIQ-20 questionnaire (Pelvic Floor Impact Questionnaire Short Form)
Description: This questionnaire allows assessment of the impact of urinary symptoms, colo-rectal-anal symptoms and genital prolapse symptoms. This questionnaire will also be used as an inclusion criterion, to homogenise the characteristics of the population in terms of pelvic dysfunction prior to the intervention, as indicated above.
Study NCT06694519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICIQ-SF (International Consultation on Incontinence Questionnaire - Short Form)
Description: a four-question self-administered questionnaire that identifies individuals with urinary incontinence by assessing frequency, severity and impact on quality of life. It is composed of five questions assessing frequency, severity and impact of UI, plus a set of eight self-diagnostic items related to UI situations experienced by patients. The maximum sum of the response values indicates a score of 21 points, referring to the high impact of UI on an individual's life.
Study NCT05288985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane catheter group in addition to Systemic Analgesia
Description: Erector spinae plane catheter is placed in the post-interventional surveillance room in the operating theatre by an anaesthetist-intensive care physician or in the MIR department by the intensive care physician in charge of the patient within 2 hours after randomisation. The local anaesthetic injected into the catheter is Ropivacaine, prescribed according to a protocol of continuous flow, bolus and refractory period. The catheter is repositioned if a secondary displacement occurs.
Study NCT05288985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Analgesia Only Group
Description: Systemic analgesia alone consists only of the 3 levels of analgesic treatment
Study NCT05351294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: All patients in Arm 2 will be seen and treated by one of three ROs with an interest in participating in this study, who will be trained by the PI to perform these visits reproducibly and with rigor. These will all be regular ROs, who like most ROs administer a mix of curative and PRT in their clinical practice; like most cancer centers, there are no ROs who formally subspecialize in PRT at our institution. Notably, patients in Arm 1 (control arm) will always have standard-of-care RO referral available for consideration of PRT if needed for symptom relief. However, patients in Arm 1 will be seen by other ROs without any specific training for this study. Any courses of PRT administered in either arm are at the discretion of the treating RO in terms of the timing, dose, fractionation, and treatment technique.
Study NCT05351294 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Early Radiation Oncology Involvement Alongside Standard Oncologic Care
Description: Early Radiation Oncology Involvement Alongside Standard Oncologic Care
Study NCT05640102 — intervention group
Intervention type: DRUG
Intervention: Zanubrutinib
Description: Dosing and treatment duration are at the discretion of the prescribing physician and in accordance with local labeling
Study NCT05540639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Mindfetalness
Description: The pregnant woman is motivated to practice Mindfetalness verbally, by video, by a leaflet and at a website.
Study NCT06553027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVN424 75 mg
Description: Participants will receive 75 mg CVN424 tablet once daily.
Study NCT06553027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVN424 150 mg
Description: Participants will receive 150 mg CVN424 tablet once daily.
Study NCT06553027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablet once daily.
Study NCT05014490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exib 120 mg etoricoxib film-coated tablets
Description: Oral, COX-2 highly selective, non-steroidal anti-inflammatory generic drug
Study NCT05014490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arcoxia® 120 mg etoricoxib film-coated tablets
Description: Oral, COX-2 highly selective, non-steroidal anti-inflammatory innovative drug
Study NCT05805202 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling and urine analysis
Description: A blood sample of 10- 20 ml from pediatric patients, 30-50 ml from adult patients will be collected for each patient and healthy voluntarees
Study NCT06694519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sandvik's test
Description: It provides information on the severity of the UI by means of two questions. The interpretation based on the score is classified as: 1-2 mild UI, 3-6 moderate UI, 8-9 severe UI, 12 very severe UI.
Study NCT05805202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling and urine analysis
Description: A blood sample of 10- 20 ml from pediatric patients, 30-50 ml from adult patients will be collected for each patient and healthy voluntarees
Study NCT05720702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: homocysteine (Hcy) lowering supplements
Description: NAFLD participants will take homocysteine (Hcy) lowering supplements daily for 12 weeks.
Study NCT05551936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m\^2 IV Days 1-2, Cycles 1-3
Study NCT05551936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV Day 1 Cycles 1-6
Study NCT05551936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: RP2D (400, 600, or 800 mg) orally twice daily Cycles 1-6
Study NCT06694519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: vaginal health index (VHI)
Description: this index consists of a graduated scale from 1 to 5 for each item (vaginal elasticity, fluid volume, pH, epithelial integrity and moisture).Vaginal elasticity ranges from 1 (no elasticity) to 5 (excellent elasticity), assessed by distension of the mucosa on palpation and speculum placement. The volume of fluid, assessed during inspection, varies between 1 (no discharge) and 5 (normal discharge) (white flocculent). The integrity of the epithelium varies between 1 (petechiae already detected on inspection) and 5 (non-friable tissue and normal mucosa). Moisture ranges from 1 (no moisture detected on inspection and presence of inflamed mucosa) to 5 (normal moisture). The pH will be quantified using a pH indicator strip between 0 and 14 (MColorpHast™-PH indicator strips) to be placed directly on the right lateral vaginal wall for one minute, giving 1 point for pH 6.1, 2 for pH 5.6-6.0, 3 for pH 5.1-5.5, 4 for pH 4.7-5.0 and 5 for pH ≤ 4.6. The sum of all items represents the vaginal health
Study NCT06694519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS)
Description: This scale allows the intensity of pain described by the patient to be measured with maximum reproducibility between observers. It consists of a horizontal line of 10 centimetres, at the ends of which are the extreme expressions of a symptom. At the left end is the absence or lowest intensity and at the right end the highest intensity. The patient is asked to mark on the line the point that indicates the intensity of the pain during sexual intercourse and it is measured with a millimetres ruler. The intensity is expressed in centimetres or millimetres. The rating will be: 1 Mild pain if the patient scores the pain as less than 3; 2 Moderate pain if the rating is between 4 and 7; 3 Severe pain if the rating is equal to or greater than 8.
Study NCT06694519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body Image Scale (S-BIS)
Description: It consists of 10 items assessing various dimensions of body image in cancer patients, evaluating: affective, behavioural and cognitive. The items are scored on a four-point scale (0: not at all; 1: a little; 2: quite a lot; 3: a lot) with a maximum possible score of 3 points. The higher the score, the higher the body image problem. Its brevity facilitates rapid assessment in both clinical and research settings. It shows a stable factor structure between samples, and good psychometric properties with high reliability (Cronbach's alpha=0.93), suggesting that it is a suitable and useful measure for assessing body image in breast cancer patients.
Study NCT06694519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Likert's scale questionnaire
Description: five-point Likert scale for satisfaction with treatment to be classified as: 1 (very dissatisfied), 2 (dissatisfied), 3 (no change), 4 (satisfied), 5 (very satisfied). Women who miss any of the RF sessions and/or whose attendance at the face-to-face physiotherapy sessions (RF and/or PFMT) does not reach 80% will be considered as not complying with the study protocol and their participation will be terminated, although they will be included in the analysis (by intention to treat).
Study NCT06694519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oxford's Scale
Description: It allows the contractile capacity of the pelvic floor muscles to be assessed. It scores from 0 to 5, as follows: if there is no contraction it is 0, if the contraction is very weak it is 1, if the contraction is weak it is 2, if the contraction is moderate/with tension/and maintained it is 3, if the contraction is good and maintains tension with resistance it is 4, and if the contraction is strong and maintains tension against a resistant force it is 5.
Study NCT06694519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sexual function and self-esteem
Description: The Female Sexual Function Index (FSFI) questionnaire consists of 19 items that assess sexual function over the past 4 weeks and performance in six domains: sexual desire, arousal, lubrication, orgasm, satisfaction and pain. A cut-off point ≤ 26.5 is considered sexual dysfunction and an increase in score is considered an improvement.
Study NCT06687720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MetBroma
Description: Mode of Usage: Take one slow-release capsule twice a day, after meal Dosage Form: Capsule Unit Dose Route of administration: Oral frequency: Twice a day
Study NCT06687720 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MetBroma
Description: Mode of Usage: Take one slow-release capsule twice a day, after meal Dosage Form: Capsule Unit Dose Route of administration: Oral frequency: Twice a day
Study NCT06687863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Includes aerobic exercise, strength training, streching
Study NCT06689332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Comprehensive geriatric assessment (CGA) is performed by a geriatrician and a geriatric nurse. CGA in this study includes: Assessment of coexisting diseases and treatments. Review of medications and adjustments as needed. Assessment of symptoms and health related issues including screening for depression, dementia, delirium, nutritional problems, falls, polypharmacy and fatigue. Objective examination including blood tests and electrocardiogram. Assessment of activities of daily living and instrumental activities of daily living through standardized questionnaires. Assessment of domestic conditions, including need for assistance from community-based health care services. Assessment of physical function through history and physical tests. Based on the CGA findings, the geriatrician will initiate relevant interventions (including investigations or treatments) and follow-up as required.
Study NCT06627595 — intervention group
Intervention type: DRUG
Intervention: Immunotherapy
Description: Patients will be treated in accordance with the guidelines for melanoma treatment.
Study NCT06693973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AcNK-Sup003 cell injection solution
Description: The AcNK technology has successfully achieved the direct, covalent, and directional conjugation of intact antibodies which includes the Fc domain to the surface of NK cells via a one-step enzymatic reaction. This novel approach yields a non-genetically modified NK cell that is conjugated with dual-targeting antibodies, referred to as AcNK. Specifically, AcNK-Sup003 cells are cryopreserved NK cells that have been conjugated with bispecific antibodies target both CD20 and CD19.
Study NCT06686901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered Therapeutic Evaluative Conditioning for Suicide (TEC-S)
Description: Therapeutic Evaluative Conditioning for Suicide (active TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair suicidal behavior stimuli (pictures, words) with other negative stimuli and self-related stimuli with positive stimuli.
Study NCT06686901 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smartphone-delivered inactive Therapeutic Evaluative Conditioning
Description: Therapeutic Evaluative Conditioning (inactive TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair positive and negative stimuli (pictures, words) with each other.
Study NCT06690372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality exercise
Description: Over the 12-weeks, participants will be instructed to exercise with the VR-Move 3x/week for 30 minutes for 12-weeks total, with modules presented in a prescribed weekly sequence to provide novel and re-enforcement of modules, while ensuring all modules are performed. Further, participants will be provided the opportunity of a 30 minute free-play of module of choice once a module has been introduced.